Cardiac transplantation: indications, eligibility and current outcomes

  title={Cardiac transplantation: indications, eligibility and current outcomes},
  author={Sai Kiran Bhagra and Stephen J Pettit and Jayan Parameshwar},
  pages={252 - 260}
### Learning objectives Despite advances in medical and device therapy, the prognosis and quality of life of patients with advanced heart failure (HF) remains poor. For a carefully selected group of these patients, cardiac transplantation is the treatment of choice. The first human-to-human heart transplant was performed in Cape Town on 3 December 1967 by Christiaan Barnard; the patient died 18 days later of infective complications. Outcomes were poor in the early years, but with the… 

Implantable left ventricular assist device: indications, eligibility and current outcomes

The indications for LVAD implantation, preoperative considerations and clinical outcomes for continuousflow LVADs (cfLVADs) used in contemporary practice are covered, and the article will focus on the current thirdgeneration centrifugal devices.

A review of the management of patients with advanced heart failure in the intensive care unit.

The clinical assessment, hemodynamic profiling and management of the patient with AcHF in the ICU, and the general principles of pre-surgical optimization encompassing individual systems (the kidneys, the liver, blood and glycemic control) will be discussed.

Cardiac Rehabilitation in a Patient With Severe Heart Failure and Ventricular Septal Defect Secondary to Acute Myocardial Infarction

In this patient, a program of CPR improved cardiac function and physical capacity, allowing him to be removed from the national waiting list for a heart transplant.

Kidney transplantation and cardiomyopathy: Concepts and controversies in clinical decision‐making

This review extracted data from published literature to understand the pathophysiologic interactions between end‐stage renal diseases with cardiomyopathy and proposed the management algorithm, which would ensure consensus across all stakeholders involved in decision‐making.

Comparison of Quality of Life Between Patients with Advanced Heart Failure and Heart Transplant Recipients

Introduction Heart transplantation is the treatment indicated for patients with advanced and refractory heart failure (HF). The transplant is expected to increase survival and improve the level of

Combined heart and liver transplantation: an updated systematic review.

Despite its complexity, CHLT is a safe and effective procedure for the management of lethal diseases that lead to progressive heart and/or liver failure, and future studies should compare CHLT with isolated cardiac and hepatic transplantations.

Donor-recipient Matching in Heart Transplantation

The aim of this article is to summarize the recent knowledge on the impact of various factors on accurate donor-recipient matching to heart transplantation.

Mechanical circulatory support devices: historical overview and modern approach

An overview of the history and indications for mechanical circulatory support (MCS), as well as how to select patients for MCS and a brief explanation of available devices are presented.



Application of the International Society for Heart and Lung Transplantation (ISHLT) criteria for primary graft dysfunction after cardiac transplantation: outcomes from a high-volume centre†

  • J. SquiersG. Saracino B. Lima
  • Medicine
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • 2017
A diagnosis of PGD portends worse outcomes including increased 30-day and 1-year mortality, and the ISHLT diagnostic criteria for moderate and severe PGD identify and discriminate patients with PGD in a clinically relevant manner.

Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors

  • A. NicoaraD. Ruffin Raquel R Bartz
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2018
There was no change in the PGD incidence; however, there was an increase in the recipient pretransplantation use of amiodarone and the rate of 30‐day mortality was significantly elevated in those with PGD versus those without PGD.

Retransplant and Medical Therapy for Cardiac Allograft Vasculopathy: International Society for Heart and Lung Transplantation Registry Analysis

Challenges associated withretransplantation as well as improved CAV treatment options support the current consensus recommendation limiting retransplant to highly selected patients with CAV.

Hepatic dysfunction and survival after orthotopic heart transplantation: application of the MELD scoring system for outcome prediction.

  • A. ChokshiF. Cheema P. Schulze
  • Medicine
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • 2012

UK guidelines for referral and assessment of adults for heart transplantation

Up-to-date information is provided about referral for transplantation, the role of left ventricular assist devices prior to transplant, patient selection, waiting-list management and donor heart availability, and the positive role that cardiologists can play in promoting and facilitating organ donation.

Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs.

This series of articles reviews mechanisms and types of rejection, immunosuppressive drugs commonly used in the heart transplant recipient, common medical problems after transplantation, and clinically significant drug–drug interactions.

Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation

It is observed that myocardial fibrosis is an important contributor to the development of restrictive physiology and further work needs to be done for risk stratification and the mechanism of fibrosis development.